Drug intelligence / Profile preview

BIC activator

Development stage: Preclinical
Lead developer: Nutshell Therapeutics
Modality: Small Molecules

Overview

Nutshell Therapeutics-BIC-small molecule-CNS is a small-molecule activator currently in the Lead to Preclinical Candidate (PCC) stage for the treatment of central nervous system (CNS) disorders. Developed by Nutshell Therapeutics, the program targets an undisclosed biological entity referred to as "BIC" (likely a placeholder for a Best-in-Class target). The company utilizes its proprietary allosteric drug discovery platform to identify and optimize small molecules that modulate protein function through non-orthosteric sites, aiming to achieve superior selectivity and therapeutic index compared to existing treatments. The specific mechanism of action and the role of the BIC target in CNS indications have not been publicly disclosed.

Other names: Nutshell Therapeutics-BIC-small molecule-CNSBIC activator (CNS)

Beyond the preview

Go deeper on BIC activator.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIC activator.

Explore the full profile